Edgar Filing: Evoke Pharma Inc - Form 4

Evoke Pharma In	c									
Form 4										
April 29, 2016								OMB A	APPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION										
Check this box Washington, D.C. 20549							Number:	3235-0287		
if no longer subject to Section 16. Form 4 or							Expires:	January 31, 2005		
						WINEKSIII OF	Estimated burden ho	urs per		
Form 5 obligations may continue. See Instruction 1(b).	Section 17	(a) of the l	Public U	tility Hol	ding Con		nge Act of 1934, of 1935 or Section 940	response on	0.5	
(Print or Type Respondence)	nses)									
1. Name and Address of Reporting Person <u>*</u> Brady Todd C			2. Issuer Name and Ticker or Trading Symbol			-	5. Relationship of Reporting Person(s) to Issuer			
.	-		Evoke Pharma Inc [EVOK]				(Check all applicable)			
(Last)	(First) (Middle)		of Earliest T Day/Year)	ransaction		_X_ Director	10	% Owner	
C/O EVOKE PH LOMAS SANTA SUITE 270			04/27/2	-			Officer (giv below)		her (specify	
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
SOLANA BEAC	LH, CA 920	15					Person		1 0	
(City) (State)	(Zip)	Tab	le I - Non-I	Derivative	Securities A	cquired, Disposed	of, or Beneficia	ally Owned	
	ansaction Date th/Day/Year)	Execution any	Date, if	3. Transactio Code (Instr. 8)	4. Securiti nAcquired Disposed (Instr. 3, 4	(A) or of (D) and 5)	Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	(A)or(D) Price	Transaction(s) (Instr. 3 and 4)			
Reminder: Report on	a separate line	e for each cl	ass of sec	urities benef	-	-	or indirectly.	ation of	SEC 1474	
					inform requir	nation cont ed to respo ys a currer	ained in this form and unless the fo ntly valid OMB co	n are not rm	(9-02)	
	Tab					posed of, or convertible s	Beneficially Owner securities)	I		
1. Title of 2.	3. Trans	saction Date	e 3A. Dee	emed	4.	5. Number	of 6. Date Exerci	sable and	7. Title and Amount of	

Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative

Underlying Securities

Expiration Date

Edgar Filing: Evoke Pharma Inc - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year)		(Instr. 3 and 4)		S (
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 4.81	04/27/2016		А	19,000	<u>(1)</u>	04/26/2026	Common Stock	19,000	
Reporting Owners										

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Brady Todd C C/O EVOKE PHARMA, INC. 505 LOMAS SANTA FE DRIVE, SUITE 270 SOLANA BEACH, CA 92075	Х					
Signatures						
/s/ Matthew J. D'Onofrio, Attorney-in-fact for T Brady	odd C.	04/29/2016				
** Signature of Reporting Person			Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant (4/27/2017), subject to the reporting person's continued service to the Issuer through such vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S (